Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31667419 | 1.00 | TNKS2 (0.49) | TNKS2HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL19573960 | 1.00 | TNKS2 (0.49) | TNKS2HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL29695366 | 1.00 | TNKS2 (0.49) | TNKS2HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL19573959 | 1.00 | TNKS2 (0.49) | TNKS2HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL20012844 | 0.88 | TNKS2 (0.42) | TNKS2HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL29031895 | 0.80 | MAPT (0.41) | TNKS2HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL15256932 | 0.79 | TNKS2 (0.46) | TNKS2HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL8293271 | 0.78 | TSHR (0.48) | TNKS2HTR2BPBRM1TSHRHSD17B10 | |
| SCHEMBL12219994 | 0.76 | MKNK2 (0.40) | TSHRHSD17B10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL17797168 | 0.75 | HSD17B10 (0.49) | TNKS2HTR2AHTR2CHTR2BPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022253252-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS | SILEXON BIOTECH CO., LTD. (CN) | 2022-12-08 | — | — | WO | claimed |
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
| US-11998901-B2 | Metal complex, method for producing same, and method for producing gamma-lactam compound using same | INSTITUTE FOR BASIC SCIENCE (KR) | 2024-06-04 | — | — | US | disclosed |
| WO-2024061340-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-03-28 | — | — | WO | disclosed |
| CN-114507177-B | Method for preparing functionalized 2- (3-oxo-isoindoline-1-subunit) methyl acetate from carbon dioxide | 常州大学 | 2023-11-21 | — | — | CN | disclosed |
| CN-111566116-B | Novel metal complex, process for producing the same, and process for producing gamma-lactam compound using the same | 基础科学研究院 | 2023-06-09 | — | — | CN | disclosed |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| WO-2022253252-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS | SILEXON BIOTECH CO., LTD. (CN) | 2022-12-08 | — | — | WO | disclosed |
| US-20220168717-A1 | NOVEL METAL COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING GAMMA-LACTAM COMPOUND USING SAME | INSTITUTE FOR BASIC SCIENCE (KR) | 2022-06-02 | — | — | US | disclosed |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-18 | — | — | US | disclosed |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-18 | — | — | US | disclosed |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-18 | — | — | US | disclosed |
| EP-2099783-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008079759-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079759-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-03 | — | — | WO | disclosed |
| US-4315940-A | Antidiabetic 1-piperidine-sulfonylureas | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-02-16 | — | — | US | disclosed |
| EP-0006587-B1 | SULFONYL UREAS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-11-11 | — | — | EP | disclosed |
| EP-0030650-A1 | 1-Piperidinesulfonyl ureas, processes for their preparation, pharmaceutical compositions based on these compounds and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-06-24 | — | — | EP | disclosed |
| EP-0006587-A1 | Sulfonyl ureas, processes for their preparation and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168717-A1 | NOVEL METAL COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING GAMMA-LACTAM COMPOUND USING SAME | COASY, NOTUM, MRPL21 | TNKS2 3192/4885HTR2A 4810/4885HTR2C 4851/4885 |
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | TNKS2 1401/4885HTR2A 1695/4885HTR2C 1873/4885 |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F7, F8, F9 | TNKS2 2887/4885HTR2A 4487/4885HTR2C 4547/4885 |
| US-11998901-B2 | Metal complex, method for producing same, and method for producing gamma-lactam compound using same | COASY, NOTUM, MRPL21 | TNKS2 3114/4885HTR2A 4805/4885HTR2C 4841/4885 |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | BET1, BRD4, PHKB | TNKS2 724/4885HTR2A 4152/4885HTR2C 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.